Patents by Inventor Ester G. Fernandez-Salas

Ester G. Fernandez-Salas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
    Patent number: 8518417
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 27, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • MODIFIED CLOSTRIDIAL TOXINS WITH ENHANCED TRANSLOCATION CAPABILITY AND ENHANCED TARGETING ACTIVITY
    Publication number: 20130203148
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: July 11, 2007
    Publication date: August 8, 2013
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20110294742
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Application
    Filed: August 15, 2011
    Publication date: December 1, 2011
    Applicant: ALLERGAN, INC.
    Inventors: LANCE E. STEWARD, ESTER G. FERNANDEZ-SALAS, MARCELLA A. GILMORE, JOSEPH FRANCIS, SHENGWEN LI, KEI ROGER AOKI
  • Degradable clostridial toxins
    Patent number: 7998489
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: August 16, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester G. Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Shengwen Li, Kei Roger Aoki
  • Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
    Patent number: 7993656
    Abstract: The invention provides modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 9, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • Optimizing Expression of Active Botulinum Toxin Type E
    Publication number: 20110111483
    Abstract: Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells.
    Type: Application
    Filed: October 14, 2010
    Publication date: May 12, 2011
    Applicant: ALLERGAN, INC.
    Inventors: LANCE E. STEWARD, MARCELLA A. GILMORE, ESTER G. FERNANDEZ-SALAS, SHENGWEN LI, RONALD G. MILLER, KEI ROGER AOKI
  • Degradable clostridial toxins
    Patent number: 7892565
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: February 22, 2011
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester G. Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Shengwen Li, Kei Roger Aoki
  • Optimizing expression of active Botulinum Toxin type E
    Patent number: 7825233
    Abstract: Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: November 2, 2010
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Marcella A. Gilmore, Ester G. Fernandez-Salas, Shengwen Li, Ronald G. Miller, Kei Roger Aoki
  • Degradable Clostridial Toxins
    Publication number: 20090023901
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Application
    Filed: August 15, 2008
    Publication date: January 22, 2009
    Inventors: Lance E. Steward, Ester G. Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Shengwen Li, Kei Roger Aoki
  • OPTIMIZING EXPRESSION OF ACTIVE BOTULINUM TOXIN TYPE A
    Publication number: 20090023198
    Abstract: Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/A in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/A from such nucleic acid molecules, expression constructs and cells.
    Type: Application
    Filed: August 15, 2008
    Publication date: January 22, 2009
    Inventors: Marcella A. Gilmore, Shengwen Li, Ester G. Fernandez-Salas, Lance E. Steward, Ronald G. Miller, Kei Roger Aoki
  • MODIFIED CLOSTRIDIAL TOXINS WITH ENHANCED TRANSLOCATION CAPABILITIES AND ALTERED TARGETING ACTIVITY FOR CLOSTRIDIAL TOXIN TARGET CELLS
    Publication number: 20080241881
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.
    Type: Application
    Filed: July 11, 2007
    Publication date: October 2, 2008
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • Degradable Clostridial Toxins
    Publication number: 20080213830
    Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.
    Type: Application
    Filed: September 1, 2005
    Publication date: September 4, 2008
    Applicant: ALLERGAN, INC.
    Inventors: Lance E. Steward, Ester G. Fernandez-Salas, Marcella A. Gilmore, Joseph Francis
  • Optimizing Expression Of Active BotulinumToxin Type E
    Publication number: 20080138893
    Abstract: Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells.
    Type: Application
    Filed: June 9, 2005
    Publication date: June 12, 2008
    Inventors: Lance E. Steward, Marcella A. Gilmore, Ester G. Fernandez-Salas, Shengwen Li, Ronald G. Miller, Kei Roger Aoki